The firm, which raised $7.1 million from its IPO last week, is looking to move into geographies where a need for infectious disease tests are already well established, its CEO said.
The commercial future of the test is uncertain, but one of its developers said that work to develop it demonstrates even mature technologies can have new clinical value.
The test was made about 10 times more sensitive than standard rapid immunoassays by tweaking a number of the firm's proprietary technologies, a company official said.
